Genomtec S.A. started key preparatory activities related to planned testing of Genomtec diagnostic devices in Asia. These activities are directly related to the ongoing M&A process and are a response to the demand expressed by potential partners in this region.
The current phase of preparatory work for the tests is organizational and analytical in nature and involves establishing a detailed scope and method of conducting local tests with stakeholders by Genomtec staff. The company is also focusing on analyzing logistical conditions, assessing the legal requirements for biosafety in the given region, and preparing and producing the appropriate number of reaction cards necessary for system validation.
Miron Tokarski, President of the Management Board and co-founder of Genomtec SA, comments:
“Undertaking preparatory steps for testing in Asia is an important step in the ongoing M&A process. The fact that potential partners with whom we are in talks have expressed a need to verify our technology in local conditions confirms the strong interest in Genomtec’s solutions in the dynamically developing Asian market and the transition to the next stage of the M&A process. We are currently in the phase of intensive logistical and organizational preparations to efficiently conduct the tests.”
The company’s flagship project is the Genomtec ID® mobile diagnostic system, which consists of an analyzer and a reaction card with integrated genetic tests. The Genomtec ID® platform is based on the proprietary SNAAT® solution and stands out from the competition for its mobility, speed, and ability to simultaneously diagnose multiple pathogens at the point of care. The OncoSNAAT® project, in turn, is a technology for detecting genetic changes occurring in cancer, which is crucial in personalized medicine, for example, when selecting targeted oncology treatments.
